Czerniecki BJ - Search Results

1

Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cells.

Berk E, Xu S, Czerniecki BJ. Berk E, et al. Among authors: czerniecki bj. Oncoimmunology. 2014 Jan 6;3:e27617. doi: 10.4161/onci.27617. eCollection 2014. Oncoimmunology. 2014. PMID: 25101219 Free PMC article.

2

High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.

Xu S, Koldovsky U, Xu M, Wang D, Fitzpatrick E, Son G, Koski G, Czerniecki BJ. Xu S, et al. Among authors: czerniecki bj. Surgery. 2006 Aug;140(2):170-8. doi: 10.1016/j.surg.2006.03.006. Surgery. 2006. PMID: 16904966

3

Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists.

Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Roses RE, et al. Among authors: czerniecki bj. J Immunol. 2008 Oct 1;181(7):5120-7. doi: 10.4049/jimmunol.181.7.5120. J Immunol. 2008. PMID: 18802116

4

Inhibition of CD4+CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine.

Lee MK 4th, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ. Lee MK 4th, et al. Among authors: czerniecki bj. PLoS One. 2013 Nov 11;8(11):e74698. doi: 10.1371/journal.pone.0074698. eCollection 2013. PLoS One. 2013. PMID: 24244265 Free PMC article. Clinical Trial.

5

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Breast Cancer Res. 2015 May 23;17(1):71. doi: 10.1186/s13058-015-0584-1. Breast Cancer Res. 2015. PMID: 25997452 Free PMC article.

6

Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.

Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Front Immunol. 2015 Jun 2;6:271. doi: 10.3389/fimmu.2015.00271. eCollection 2015. Front Immunol. 2015. PMID: 26082780 Free PMC article. Review.

7

Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy.

Terhune J, Berk E, Czerniecki BJ. Terhune J, et al. Among authors: czerniecki bj. Vaccines (Basel). 2013 Nov 21;1(4):527-49. doi: 10.3390/vaccines1040527. Vaccines (Basel). 2013. PMID: 26344346 Free PMC article. Review.

8

Progressive loss of anti-HER2 CD4⁺ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.

Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E, Hoyt C, Feldman MD, Zhang PJ, Xu S, Koski GK, Czerniecki BJ. Datta J, et al. Among authors: czerniecki bj. Oncoimmunology. 2015 Apr 1;4(10):e1022301. doi: 10.1080/2162402X.2015.1022301. eCollection 2015 Oct. Oncoimmunology. 2015. PMID: 26451293 Free PMC article.

9

CD4⁺ Th1 to the rescue in HER-2+ breast cancer.

Lowenfeld L, Xu S, Czerniecki BJ. Lowenfeld L, et al. Among authors: czerniecki bj. Oncoimmunology. 2018 May 2;8(10):e1078062. doi: 10.1080/2162402X.2015.1078062. eCollection 2019. Oncoimmunology. 2018. PMID: 31646065 Free PMC article.

10

Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells.

Prabakaran I, Menon C, Xu S, Gómez-Yafal A, Czerniecki BJ, Fraker DL. Prabakaran I, et al. Among authors: czerniecki bj. Ann Surg Oncol. 2002 May;9(4):411-8. doi: 10.1007/BF02573878. Ann Surg Oncol. 2002. PMID: 11986195

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page